A carregar...
Combination use of medicines from two classes of renin–angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function
European and United States regulatory agencies recently issued warnings against the use of dual renin–angiotensin system (RAS) blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs) or aliskiren in any patient, based on...
Na minha lista:
| Publicado no: | Ther Adv Drug Saf |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4530349/ https://ncbi.nlm.nih.gov/pubmed/26301070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098615589905 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|